Terumo Reports Strong Q1 Revenue Growth, Ups Guidance Amid Tax Refunds and Settlement Income

TOKYO, Aug 07 (Pulse News Wire) – Terumo Corporation (4543.T) reported robust revenue growth for the quarter ending June 30, 2026, with sales increasing 19.9% to ¥1,454.67 billion compared to the same period last year. Adjusted operating income surged 34.7%, driven by strong performance across various segments, particularly in international markets.

The company's global operations saw significant expansion, especially in North America and Europe, contributing to overall growth. In Japan, solid performances in neurology and hospital care solutions bolstered domestic revenues. Additionally, Terumo acquired Organoxs, Ltd. in full during the quarter, enhancing its organ technologies division.

For the fiscal year ending March 31, 2027, Terumo revised its guidance upward due to tax refunds and settlement income. Operating profit, ordinary profit, and net profit forecasts were adjusted accordingly. Capital increased to ¥1 trillion ¥24.4 billion, reflecting higher quarterly profits and favorable exchange rates. Terumo plans to hold an earnings briefing for analysts and institutional investors to further discuss these results and outlook.